Anne-Marie Mes-Masson
Overview
Explore the profile of Anne-Marie Mes-Masson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
226
Citations
5494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, et al.
Cell Rep
. 2025 Mar;
44(3):115365.
PMID: 40023845
Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared to mutant BRAF and NRAS, the role of NF1...
2.
Meunier A, Hernandez-Castro J, Chahley N, Communal L, Kheireddine S, Koushki N, et al.
Commun Med (Lond)
. 2025 Feb;
5(1):33.
PMID: 39900650
Background: Circulating tumor cells (CTCs) are rare (a few cells per milliliter of blood) and mostly isolated as single-cell CTCs (scCTCs). CTC clusters (cCTCs), even rarer, are of growing interest,...
3.
Reen V, DAmbrosio M, Sogaard P, Tyson K, Leeke B, Clement I, et al.
Sci Adv
. 2025 Jan;
11(3):eadn2811.
PMID: 39813356
Induction of senescence by chemotherapeutic agents arrests cancer cells and activates immune surveillance responses to contribute to therapy outcomes. In this investigation, we searched for ways to enhance the NK-mediated...
4.
Geoffroy K, Viens M, Kalin E, Boudhraa Z, Roy D, Wu J, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770503
Ovarian cancer is the deadliest gynecologic cancer, and with the majority of patients dying within the first five years of diagnosis, new therapeutic options are required. The small guanosine triphosphatase...
5.
Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier M, et al.
Nat Commun
. 2024 May;
15(1):4011.
PMID: 38740764
No abstract available.
6.
Sauriol S, Carmona E, Udaskin M, Radulovich N, Leclerc-Desaulniers K, Rottapel R, et al.
Sci Rep
. 2024 May;
14(1):10017.
PMID: 38693303
No abstract available.
7.
Mes-Masson A
Biochem Cell Biol
. 2024 Apr;
102(4):299-304.
PMID: 38640502
I was fortunate enough to start my career at what was the dawn of modern-day molecular biology and to apply it to an important health problem. While my early work...
8.
Nersesian S, Arseneau R, Mejia J, Lee S, Westhaver L, Griffiths N, et al.
Front Immunol
. 2024 Feb;
14:1307873.
PMID: 38318505
Background: For patients with high grade serous carcinoma of the ovary (HGSC), survival rates have remained static for the last half century. Despite the presence of tumor mutations and infiltration...
9.
da Veiga Moreira J, Nleme N, Schwartz L, Leclerc-Desaulniers K, Carmona E, Mes-Masson A, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254843
Ovarian cancer remains a significant challenge, especially in platinum-resistant cases where treatment options are limited. In this study, we investigated the potential of methylene blue (MB) as a metabolic therapy...
10.
Brassard J, Hughes M, Dean P, Hernaez D, Thornton S, Banville A, et al.
Front Oncol
. 2024 Jan;
13:1286754.
PMID: 38188285
Introduction: Targeted-immunotherapies such as antibody-drug conjugates (ADC), chimeric antigen receptor (CAR) T cells or bispecific T-cell engagers (eg, BiTE) all aim to improve cancer treatment by directly targeting cancer cells...